Divi's Q1: consolidated PAT surges 65% to ₹902 Cr on sharp margin expansion

Divi's Laboratories delivered a strong Q1 FY27, with consolidated revenue of ₹3,080 Cr (+27.8% YoY, +8.8% QoQ) and consolidated PAT of ₹902 Cr (+65.5% YoY, +20.1% QoQ) — a clean print with no exceptional items on either side, so reported and underlying growth are identical. The headline story is profitability: consolidated net margin expanded to ~28.7% of total income from ~21.6% a year ago, and operating margin widened to roughly 40% versus 30.3% in the year-ago quarter. The lever was cost of materials consumed falling to ~49% of revenue-from-operations alongside a large ₹517 Cr inventory build, pointing to a richer product mix and operating leverage as volumes scaled. Standalone told the same story — PAT ₹891 Cr (+60% YoY) on revenue ₹2,974 Cr (+26.2%) — so consolidated and standalone do not diverge materially.

The print comfortably beat both the Street and our own pre-result bar. Consensus previews had pencilled in roughly ₹2,653–2,806 Cr of revenue with margins merely "stable"; actual revenue of ₹3,080 Cr and consolidated EPS of ₹33.95 (vs a ~₹24.75 street estimate) blew past that on both the topline and, more decisively, on margins. Against management's own Q4 guidance of "continued double-digit revenue growth" and "stable profitability despite cost pressures," the company over-delivered — +27.8% revenue growth and clear margin expansion rather than the flagged "stable" outcome. The two pre-result watch items we flagged both resolved positively: revenue beat, and margin didn't just hold but expanded.

The stock went into the print at ₹8,056, up 20.6% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Small forex loss of ₹7 Cr (consolidated) this quarter vs a ₹39 Cr forex gain year-ago

On corporate developments, the board also cleared two senior-management (procurement) appointments effective August 1 and the quarter carried a ₹30/share dividend (record date July 24, AGM August 10); a routine senior-management retirement was noted July 31 — none of these are financially material to the print. The one caveat for next quarter is that the CDMO and peptide catalysts that underpin the stock's premium valuation (P/E ~70x) are, per management, an FY28 story — this quarter's beat is driven by the base custom-synthesis/API business and mix, not yet by the new capacity ramp.